

---

**SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

**SCHEDULE 13D**

Under the Securities Exchange Act of 1934

**(Amendment No. 2)\***

**CAMP4 THERAPEUTICS CORPORATION**

---

**(Name of Issuer)**

**Common Stock, \$0.0001 par value per share**

---

**(Title of Class of Securities)**

**13463J101**

---

**(CUSIP Number)**

**James P. Boylan**  
**Enavate Sciences, 106 W 56th Street, 8th Floor**  
**New York, NY, 10019**  
**(332) 275-5551**

---

**(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)**

**12/19/2025**

---

**(Date of Event Which Requires Filing of This Statement)**

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

---

**SCHEDULE 13D**

**CUSIP No.** 13463J101

Name of reporting person

1

Enavate Sciences GP, LLC

2

Check the appropriate box if a member of a Group (See Instructions)

(a)

(b)

3 SEC use only  
Source of funds (See Instructions)

4 AF  
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

5   
Citizenship or place of organization

6 DELAWARE

Sole Voting Power

7

0.00

Number of  
Shares

Shared Voting Power

Beneficially 8

3,127,360.00

Owned by

Sole Dispositive Power

Each

9

0.00

Reporting

Person

Shared Dispositive Power

With:

10

3,127,360.00

Aggregate amount beneficially owned by each reporting person

11 3,127,360.00

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

12   
Percent of class represented by amount in Row (11)

13 6.0 %

Type of Reporting Person (See Instructions)

14 OO

## SCHEDULE 13D

**CUSIP No.** 13463J101

Name of reporting person

1 Everest Aggregator, LP

Check the appropriate box if a member of a Group (See Instructions)

2  (a)  
 (b)

3 SEC use only  
Source of funds (See Instructions)

4 WC  
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

5   
Citizenship or place of organization

6 DELAWARE

Number of 7 Sole Voting Power

Shares Beneficially Owned by Each Reporting Person With: 0.00  
 Shared Voting Power 8  
 3,127,360.00  
 Sole Dispositive Power 9  
 0.00  
 Shared Dispositive Power 10  
 3,127,360.00  
 Aggregate amount beneficially owned by each reporting person  
 11 3,127,360.00  
 Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)  
 12   
 Percent of class represented by amount in Row (11)  
 13 6.0 %  
 Type of Reporting Person (See Instructions)  
 14 PN

## SCHEDULE 13D

### Item 1. Security and Issuer

Title of Class of Securities:

(a) Common Stock, \$0.0001 par value per share

Name of Issuer:

(b) CAMP4 THERAPEUTICS CORPORATION

Address of Issuer's Principal Executive Offices:

(c) One Kendall Square, Building 1400 West, 3rd Floor, Cambridge, MASSACHUSETTS , 02139.

**Item 1 Comment:** This Amendment No. 2 (this "Amendment No. 2" or this "Schedule 13D/A") amends and supplements the statement on Schedule 13D originally filed with the Securities and Exchange Commission (the "SEC") on October 22, 2024 and amended on September 15, 2025 (as amended, the "Statement") by the Reporting Entities. Unless otherwise defined herein, capitalized terms used in this Amendment No. 2 shall have the meanings ascribed to them in the Statement. Unless amended or supplemented below, the information in the Statement remains unchanged.

### Item 5. Interest in Securities of the Issuer

Rows 11 and 13 of each Reporting Entities' cover page to this Schedule 13D/A set forth the aggregate number of shares of Common Stock and percentages of the shares of Common Stock beneficially owned by such Reporting Entity and are incorporated by reference. The percentage set forth in each row 13 is based upon the sum of (i) 46,881,134 shares of Common Stock outstanding as of November 3, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 6, 2025 and (ii) 5,000,000 shares of Common Stock issued in the Issuer's public offering of equity securities that closed on December 19, 2025. Everest LP directly holds 3,127,360 shares of Common Stock. Enavate GP is the general partner of Everest LP and shares voting and investment authority over the shares held by Everest LP.

(a) Rows 7 through 10 of each Reporting Entities' cover page to this Schedule 13D/A set forth the number of shares of Common Stock as to which such Reporting Entity has the sole or shared power to vote or direct the vote and sole or shared power to dispose or to direct the disposition and are incorporated by reference.

(b) Except as set forth below, none of the Reporting Entities has effected any transactions with respect to the securities of the Issuer during the past sixty days. On December 16, 2025, Everest LP sold an aggregate of 50,000 shares in open market transactions at prices ranging from \$6.50 to \$6.94 (weighted average sales price of \$6.65 per share). On December 17, 2025, Everest LP sold an aggregate of 50,000 shares in open market transactions at prices ranging from \$6.75 to \$7.20 (weighted average sales price of \$6.87 per share). On December 18, 2025, Everest LP sold an aggregate of 168,560 shares in open market transactions at prices ranging from \$6.25 to \$6.90 (weighted average sales price of \$6.52 per share). On December 19, 2025, Everest LP sold an aggregate of 310,121 shares in open market transactions at prices ranging from \$6.30 to \$6.50 (weighted average sales price of \$6.31 per share). On

December 22, 2025, Everest LP sold an aggregate of 74,316 shares in open market transactions at prices ranging from \$6.05 to \$6.37 (weighted average sales price of \$6.12 per share). On December 23, 2025, Everest LP sold an aggregate of 5,445 shares in open market transactions at prices ranging from \$6.05 to \$6.31 (weighted average sales price of \$6.10 per share).

- (d) No other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of the Common Stock.
- (e) Not applicable.

Item 7. Material to be Filed as Exhibits.

Exhibit 99.1 Joint Filing Agreement (incorporated by reference to Exhibit A to the Reporting Entities' Schedule 13D filed with the SEC on October 22, 2024).

#### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Enavate Sciences GP, LLC

Signature: /s/ James P. Boylan

Name/Title: By James P. Boylan, Manager

Date: 12/23/2025

Everest Aggregator, LP

Signature: /s/ James P. Boylan

Name/Title: By: Enavate Sciences GP, LLC, its General Partner, By James P. Boylan, Manager

Date: 12/23/2025